nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2018-5-2-60-65nodgo-387Research ArticleСЛУЧАЙ ИЗ ПРАКТИКИCASE STUDYСлучай развития костной токсичности, имитирующей рецидив основного заболевания, у ребенка с нейробластомой на фоне терапии 13-цис-Ретиноевой кислотойThe case of development of bone toxicity, simulating a relapse of the underlying disease, in a child with neuroblastoma on the background of therapy with 13-cis-Retinoic acidСагоянГ. Б.SagoyanG. B.sagoyan-garik@mail.ruШаманскаяТ. В.ShamanskayaT. V.КачановД. Ю.KachanovD. Yu.БольшаковН. А.BolshakovN. A.ТерещенкоГ. В.TereshchenkoG. V.ЛикарьЮ. Н.LikarYu. N.ВарфоломееваС. Р.VarfolomeevaS. R.ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава РоссииРоссияDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaRussian Federation201823042018526065Copyright © Сагоян Г.Б., Шаманская Т.В., Качанов Д.Ю., Большаков Н.А., Терещенко Г.В., Ликарь Ю.Н., Варфоломеева С.Р., 20182018Сагоян Г.Б., Шаманская Т.В., Качанов Д.Ю., Большаков Н.А., Терещенко Г.В., Ликарь Ю.Н., Варфоломеева С.Р.Sagoyan G.B., Shamanskaya T.V., Kachanov D.Y., Bolshakov N.A., Tereshchenko G.V., Likar Y.N., Varfolomeeva S.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/387

В статье представлен случай развития поражения костной ткани как проявление токсичности на фоне проведения дифференцировочной терапии 13-цис-Ретиноевой кислотой у пациента с нейробластомой (НБ) группы высокого риска. Данный клинический пример представляет собой интерес как модель дифференциального диагноза метастатического поражения костной ткани у пациентов с диссеминированной НБ и редкого варианта костной токсичности на фоне проведения специфической терапии.

 

The article presents a case of development of bone tissue damage as a manifestation of toxicity against the background of differentiation therapy of 13-cis-Retinoic acid in a patient with neuroblastoma (NB) of a high-risk group. This clinical example is of interest as a model of a differential diagnosis of metastatic osseous lesion in patients with disseminated NB and a rare variant of bone toxicity during specific therapy.

нейробластомадети13-цис-Ретиноевая кислотакостные метастазысцинтиграфия с 123I-метайодбензилгуанидиномneuroblastomachildren13-cis-Retinoic acidbone metastasesscintigraphy with 123I-metaiodobenzylguanidineReferencesGoodman M.S., Gurney J.G., Smith M.A. еt al. Sympathetic nervous system tumors. In: Ries L.A.G., Smith M.A., Gurney J.G. (eds.). Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute, SEER Program. NIH Pub. No. 99- 4649. Bethesda, MD; 1999. Pp. 65–72.Goodman M.S., Gurney J.G., Smith M.A. еt al. Sympathetic nervous system tumors. In: Ries L.A.G., Smith M.A., Gurney J.G. (eds.). Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute, SEER Program. NIH Pub. No. 99- 4649. Bethesda, MD; 1999. Pp. 65–72.Peinemann F., van Dalen E.C., Enk H., Berthold F. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev 2017;8:CD010685. doi: 10.1002/14651858.CD010685.pub3.Peinemann F., van Dalen E.C., Enk H., Berthold F. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev 2017;8:CD010685. doi: 10.1002/14651858.CD010685.pub3.Spix C., Pastore G., Sankila R. et al. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42(13):2081–91. doi: 10.1016/j. ejca.2006.05.008.Spix C., Pastore G., Sankila R. et al. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42(13):2081–91. doi: 10.1016/j. ejca.2006.05.008.Kushner B.H., LaQuaglia M.P., Bonilla M. A. et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994;12(12):2607–13. doi: 10.1200/JCO.1994.12.12.2607Kushner B.H., LaQuaglia M.P., Bonilla M. A. et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994;12(12):2607–13. doi: 10.1200/JCO.1994.12.12.2607Seeger R.C., Reynolds C.P. Neuroblastoma. In: Bone Marrow Transplantation. Edited by S.J. Forman, K.G. Blume, E.D. Thomas. Cambridg, England: Blacwell, 1994. Pp. 814–826.Seeger R.C., Reynolds C.P. Neuroblastoma. In: Bone Marrow Transplantation. Edited by S.J. Forman, K.G. Blume, E.D. Thomas. Cambridg, England: Blacwell, 1994. Pp. 814–826.Matthay K.K., Vallablanca I.G., Seeger R.S. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999;341(16):1165– 73. doi: 10.1056/NEJM199910143411601.Matthay K.K., Vallablanca I.G., Seeger R.S. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999;341(16):1165– 73. doi: 10.1056/NEJM199910143411601.Ikeda H., August C.S., Goldwein J.W. et al. Sites of relapse in patient with neuroblastoma following bone marrow transplantation in relation to preparatory "debulking" treatments. J Pediatr Surg 1992;27(11):1438– 41. PMID: 1479507.Ikeda H., August C.S., Goldwein J.W. et al. Sites of relapse in patient with neuroblastoma following bone marrow transplantation in relation to preparatory "debulking" treatments. J Pediatr Surg 1992;27(11):1438– 41. PMID: 1479507.Villablanca J.G., Khan A.A., Avramis V.I. et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 1995;13(4):894–901. doi: 10.1200/ JCO.1995.13.4.894.Villablanca J.G., Khan A.A., Avramis V.I. et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 1995;13(4):894–901. doi: 10.1200/ JCO.1995.13.4.894.Gota V., Chinnaswamy G., Vora T. et al. Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients. Cancer Chemother Pharmacol 2016;78(4):763–8. doi: 10.1007/s00280-016-3126-3.Gota V., Chinnaswamy G., Vora T. et al. Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients. Cancer Chemother Pharmacol 2016;78(4):763–8. doi: 10.1007/s00280-016-3126-3.Matthay K.K. Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption. Clin Cancer Res 2013;19(2):311–3. doi: 10.1158/1078-0432.CCR-12-3313.Matthay K.K. Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption. Clin Cancer Res 2013;19(2):311–3. doi: 10.1158/1078-0432.CCR-12-3313.Cross S.F., Pozza L.D., Munns C.F. Hypercalcemia and osteoblastic lesions induced by 13-cis-retinoic acid mimicking relapsed neuroblastoma. Pediatr Blood Cancer 2009;53(4):666–8. doi: 10.1002/ pbc.22052.Cross S.F., Pozza L.D., Munns C.F. Hypercalcemia and osteoblastic lesions induced by 13-cis-retinoic acid mimicking relapsed neuroblastoma. Pediatr Blood Cancer 2009;53(4):666–8. doi: 10.1002/ pbc.22052.Marabelle A., Sapin V., Rousseau R. Hypercalcemia and 13-cis-retinoic acid in post-consolidation therapy of neuroblastoma. Pediatr Blood Cancer 2009;52(2):280–3. doi: 10.1002/ pbc.21768.Marabelle A., Sapin V., Rousseau R. Hypercalcemia and 13-cis-retinoic acid in post-consolidation therapy of neuroblastoma. Pediatr Blood Cancer 2009;52(2):280–3. doi: 10.1002/ pbc.21768.DiGiovanna J.J. Isotretinoin effects on bone. J Am Acad Dermatol 2001;45(5):S176–82. doi: 10.1067/ mjd.2001.113721.DiGiovanna J.J. Isotretinoin effects on bone. J Am Acad Dermatol 2001;45(5):S176–82. doi: 10.1067/ mjd.2001.113721.Atalay A., Altaykan A., Ergin G., Kutsal Y.G. Reversible sclerotic changes of lumbar spine and femur due to long-term oral Isotretinoin therapy. Rhuematol Int 2004;24(5):197–300. doi: 10.1007/s00296- 003-0391-3.Atalay A., Altaykan A., Ergin G., Kutsal Y.G. Reversible sclerotic changes of lumbar spine and femur due to long-term oral Isotretinoin therapy. Rhuematol Int 2004;24(5):197–300. doi: 10.1007/s00296- 003-0391-3.van Beek E., Löwik C., Karperien M., Papapoulos S. Independent pathways in the modulation of osteoclastic resorptioin by intermediates of the mevalonate biosynthetic pathway: The role of the retinoic acid receptor. Bone 2006;38(2):167–71. doi: 10.1016/j.bone.2005.08.011.van Beek E., Löwik C., Karperien M., Papapoulos S. Independent pathways in the modulation of osteoclastic resorptioin by intermediates of the mevalonate biosynthetic pathway: The role of the retinoic acid receptor. Bone 2006;38(2):167–71. doi: 10.1016/j.bone.2005.08.011.Suillington J., Choy L., Derynck R. Bone morphogenetic protein and retinoic acid signaling cooperate to induce osteoblast differentiation of preadipocytes. J Cell Biol 2002;159(1):135–46. doi: 10.1083/ jcb.200204060.Suillington J., Choy L., Derynck R. Bone morphogenetic protein and retinoic acid signaling cooperate to induce osteoblast differentiation of preadipocytes. J Cell Biol 2002;159(1):135–46. doi: 10.1083/ jcb.200204060.

The authors declare that there are no conflicts of interest present.